Pharmaceutical-Grade Peptide APIs

Supply chain infrastructure for 503A / 503B compounding.

cGMP-sourced active pharmaceutical ingredients with full COA traceability — built for pharmacies that need to verify, not just trust, what's in the batch.

Regulatory Status Ledger
LAST SYNCED: PCAC JUL 2026 CYCLE
Sermorelin
CAS 86168-78-7
Eligible
503A / 503B
NAD+
CAS 53-84-9
Eligible
503A / 503B
Gonadorelin
CAS 33515-09-2
Eligible
503A / 503B
BPC-157
CAS 137525-51-0
Under Review
PCAC 2026-07
TB-500
CAS 885340-08-3
Under Review
PCAC 2026-07
KPV
CAS 66919-88-4
Under Review
PCAC 2026-07
cGMP
Facility-sourced APIs
100%
Batches third-party tested
US
Based, domestic fulfillment
DMF
On file for core compounds
Catalog

Peptide APIs, by current eligibility status.

Pricing is gated to registered, license-verified pharmacies. Every listing links to its current Certificate of Analysis.

Sermorelin
CAS 86168-78-7
Eligible
PURITY≥99.0% HPLC
FORMLyophilized powder
PACKAGING2mg / 5mg / 10mg vial
View spec sheet →
NAD+
CAS 53-84-9
Eligible
PURITY≥99.0% HPLC
FORMLyophilized powder
PACKAGING100mg / 500mg / 1g
View spec sheet →
Gonadorelin
CAS 33515-09-2
Eligible
PURITY≥99.0% HPLC
FORMLyophilized powder
PACKAGING1mg / 2mg vial
View spec sheet →
BPC-157
CAS 137525-51-0
Pending
PURITY≥99.0% HPLC
FORMLyophilized powder
STATUSPCAC 2026-07 review
Notify me on ruling →
TB-500
CAS 885340-08-3
Pending
PURITY≥99.0% HPLC
FORMLyophilized powder
STATUSPCAC 2026-07 review
Notify me on ruling →
KPV
CAS 66919-88-4
Pending
PURITY≥99.0% HPLC
FORMLyophilized powder
STATUSPCAC 2026-07 review
Notify me on ruling →
Compliance

Built around the framework you're audited against.

We track the FDA bulks lists and PCAC outcomes directly — eligibility status on this site reflects the current cycle, not a static claim.

503A Traditional compounding

State-licensed pharmacies compounding patient-specific prescriptions. Eligible APIs must appear on the applicable bulks list or meet USP/component standards.

  • Patient-specific prescription required
  • State board of pharmacy oversight
  • Bulk substance must meet §503A criteria

503B Outsourcing facilities

FDA-registered outsourcing facilities compounding without patient-specific prescriptions, under cGMP requirements closer to conventional manufacturing.

  • FDA facility registration required
  • cGMP compliance, routine FDA inspection
  • Sources from the 503B bulks list only
STEP 1

Incoming COA review

Every lot verified against supplier certificate before intake.

STEP 2

Third-party HPLC/MS

Independent lab re-verifies identity and purity.

STEP 3

Chain-of-custody log

Lot tracked from receipt through fulfillment.

STEP 4

COA released with order

Documentation ships with every unit, no request needed.

For Pharmacies

Getting an account set up.

Access and pricing are limited to verified pharmacies. Here's what that process looks like.

01

Submit license documentation

State pharmacy license and, where applicable, DEA registration and 503B facility registration.

02

Verification review

We confirm license status directly with the issuing board before account activation.

03

Account approval & pricing access

Approved accounts get catalog pricing, order history, and direct COA access per lot.

04

Ordering & fulfillment

Standard lead times and minimum order quantities are confirmed at quote — no surprises at checkout.

Request quote access.

Tell us about your pharmacy and what you're looking to source. We'll follow up to verify licensing and get you catalog access.

Have ready: state pharmacy license #
Have ready: DEA registration (if applicable)
Have ready: 503B facility registration (if applicable)
Placeholder form — wire up to your CRM/email backend before launch.